Advances in diagnosis and treatment of malignant pleural mesothelioma

Oncology Reviews

Volumn 1, Issue 2, 2007, Pages 91-102

  Scagliotti, Giorgio Vittorio ^a   Selvaggi, Giovanni ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Chemotherapy; Epidermal Growth Factor; Malignant Pleural Mesothelioma; Mesothelin; Osteopontin; Pemetrexed; Prognostic Factors; Targeted Therapy; Vascular Endothelial Growth Factor

Indexed keywords

EID: 79952259392     PISSN: 19705557     EISSN: 19705565     Source Type: Journal    
DOI: 10.1007/s12156-007-0011-7     Document Type: Review

References (107)

1. Lanphear BP, Buncher CR (1992) Latent period for malignant mesothelioma of occupational origin. J Occup Med 34:718-721
2. Peto J, Decarli A, La Vecchia C et al (1999) The European mesothelioma epidemic. Br J Cancer 79:666-672 (Pubitemid 29046253)
3. Britton M (2002) The epidemiology of mesothelioma. Semin Oncol 29:18-25 (Pubitemid 34163531)
4. Hodgson JT, Darnton A (2000) The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure. Ann Occup Hyg 44:565-601
5. Robinson BW, Musk AW, Lake RA (2005) Malignant mesothelioma. Lancet 366:397-408 (Pubitemid 41073959)
6. Montanaro F, Bray F, Gennaro V et al (2003) Pleural mesothelioma incidence in Europe: evidence of some deceleration in the increasing trends. Cancer Causes Control 14:791-803 (Pubitemid 37463893)
7. Price B (1997) Analysis of current trends in United States mesothelioma incidence. Am J Epidemiol 145:211-218
8. Carbone M, Kratzke RA, Testa JR (2002) The pathogenesis of mesothelioma. Semin Oncol 29:2-17 (Pubitemid 34163530)
9. Herndon JE, Green MR, Chainian AP et al (1998) Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 113:723-731 (Pubitemid 28130949)
10. Edwards JG, Abrams KR, Leverment JN et al (2000) Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax 55:731-735 (Pubitemid 30660898)
11. Segal A, Whitaker D, Henderson D et al (2002) Pathology of mesothelioma. In: Robinson BWS, Chahinian AP, (eds) Mesothelioma. Dunitz M, London pp143-184
12. Ordoñez NG (1998) Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma. Mod Pathol 11:929-933 (Pubitemid 28487209)
13. Oates J, Edwards C (2000) HBME-1, MOC-31, WT1 and calretinin: as assessment of recently described markers for mesothelioma and adenocarcinoma. Histopathology 36:341-347 (Pubitemid 30198916)
14. Ordonez NG (2005) D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. Hum Pathol 36:372-380 (Pubitemid 40591807)
15. Kushitani K, Takeshima Y, Amatya VJ et al (2007) Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma. Pathol Int 57:190-199 (Pubitemid 46279947)
16. Mimura T, Ito A, Sakuma T et al (2007) Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma. Cancer 109:933-938 (Pubitemid 46333535)
17. Doviner V, Maly B, Reinhartz T et al (2007) Heparanase expression: a potential ancillary diagnostic tool for distinguishing between malignant cells and reactive mesothelium in body cavity effusions. Cytopathology 18:13-19 (Pubitemid 46155239)
18. Kato Y, Tsuta K, Seki K et al (2007) Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol 20:215-220 (Pubitemid 46422176)
19. Welker L, Muller M, Holz O et al (2007) Cytological diagnosis of malignant mesothelioma-improvement by additional analysis of hyaluronic acid in pleural effusions. Virchows Arch 450:455-461 (Pubitemid 46466389)
20. Robinson BW, Lake RA (2005) Advances in malignant mesothelioma. N Eng J Med 353:1591-1603 (Pubitemid 41434638)
21. Ashkar S, Weber GF, Panoutsakopoulou V et al (2000) Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 287:860-864 (Pubitemid 30084330)
22. Pass HI, Lott D, Lonardo F et al (2005) Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 353:1564-1573 (Pubitemid 41434635)
23. Kim JH, Skates SJ, Uede T et al (2002) Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 287:1671-1679 (Pubitemid 34289219)
24. Chambers AF, Wilson SM, Kerkvliet N et al (1996) Osteopontin expression in lung cancer. Lung Cancer 15:311-323 (Pubitemid 26399511)
25. Fedarko NS, Jain A, Karadag A et al (2001) Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 7:4060-4066 (Pubitemid 34044628)
26. O'Regan A (2003) The role of osteopontin in lung disease. Cytokine Growth Factor Rev 14:479-488 (Pubitemid 37296021)
27. Ordonez NG (2003) Application of mesothelin immunostaining in tumour diagnosis. Am J Surg Pathol 27:1418-1428 (Pubitemid 37315193)
28. Hellstrom I, Raycraft J, Kanan S et al (2006) Mesothelin variant 1 is released from tumour cells as a diagnostic marker. Cancer Epidemiol Biomarkers Prev 15:1014-1020 (Pubitemid 43823532)
29. Scherpereel A, Grigoriu BD, Conti M et al (2006) Soluble mesothelin-related protein in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 173:1155-1160 (Pubitemid 43726897)
30. Beyer HL, Geschwindt RD, Glover CL, et al (2007) MESOMARK: a potential test for malignant pleural mesothelioma. Clin Chem 53:666-672 (Pubitemid 46580236)
31. Di Serio F, Fontana A, Loizzi M et al (2007) Mesothelin family proteins and diagnosis of mesothelioma: analytical evaluation of an automated immunoassay and preliminary clinical results. Clin Chem Lab Med 45:634-638 (Pubitemid 46709735)
32. Creaney J, Yeoman D, Naumoff L et al (2007) Soluble mesothelin in effusions - a useful tool for the diagnosis of malignant mesothelioma. Thorax 62:569-576 (Pubitemid 47056881)
33. Grigoriu BD, Scherpereel A, Devos P et al (2007) Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment. Clin Cancer Res 13:2928-2935 (Pubitemid 46850705)
34. Shiomi K, Miyamoto H, Segawa T et al (2006) Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients. Cancer Sci 97:928-932 (Pubitemid 44151275)
35. Wang ZJ, Reddy GP, Gotway MB et al (2004) Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET. Radiographics 24:105-119 (Pubitemid 38134597)
36. Rusch VW (1995) A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Chest 108:1122-1128
37. Chaisawong K, Aach T, Jager P et al (2007) Computer-assisted diagnosis for early stage pleural mesothelioma. Methods Inf Med 46:324-331
38. Carretta A, Landoni C, Melloni G et al (2000) 18-FDG positron emission tomography in the evaluation of malignant pleural diseases: A pilot study. Eur J Cardiothorac Surg 17:377-383 (Pubitemid 30204484)
39. Flores RM, Akhurst T, Gonen M et al (2006) Positron emission tomography predicts survival in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 132:763-768 (Pubitemid 44415880)
40. Ceresoli GL, Chiti A, Zucali PA et al (2006) Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose. J Clin Oncol 24:4587-4593 (Pubitemid 46630956)
41. Waller DA. The role of surgery in diagnosis and treatment of malignant pleural mesothelioma. Curr Opin Oncol 2003;15:139-143 (Pubitemid 36324220)
42. Pass HI, Kranda K, Temeck BK et al (1997) Surgically debulked malignant pleural mesothelioma: results and prognostic factors. Ann Surg Oncol 4:215-222 (Pubitemid 127725247)
43. Ball DL, Cruickshank DG (1990) The treatment of malignant mesothelioma of the pleura: review of a 5-year experience, with special reference to radiotherapy. Am J Clin Oncol 13:4-9 (Pubitemid 20114548)
44. Boutin C, Rey F, Viallat JR (1995) Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest 108:754-758
45. Ahamad C, Stevens CW, Smythe WR et al (2003) Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMRT) to the chest. Cancer J 9:476-484 (Pubitemid 44403485)
46. Flores RM (2005) Induction chemotherapy, extrapleural pneumonectomy, and radiotherapy in the treatment of malignant pleural mesothelioma: the Memorial Sloan-Kettering experience. Lung Cancer 49: S71-S74 (Pubitemid 40798851)
47. Krug LM, Pass H, Rusch VW et al (2007) A multicenter U.S. trial of neoadjuvant pemetrexed plus cisplatin (PC) followed by extrapleural pneumonectomy (EPP) and hemithoracic radiation (RT) for stage I-III malignant pleural mesothelioma (MPM). Proceedings of the ASCO 43rd Annual Meeting June 1-5, 2007 Chicago, IL, USA, J Clin Oncol 25 [Suppl 18]: [Abstract #7561]
48. Ellis P, Davies AM, Haynes AE et al (2006) The Use of Chemotherapy in Patients with Advanced Malignant Pleural Mesothelioma: A Systematic Review and Practice Guideline. J Thorac Oncol 1:591-601 (Pubitemid 47181411)
49. Zidar BL, Green S, Pierce HI et al (1988) A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group Study. Invest New Drugs 6:223-226
50. Sorensen PG, Bach F, Bork E et al (1985) Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma. Cancer Treat Rep 69:1431-1432 (Pubitemid 16163084)
51. Solheim OP, Saeter G, Finnanger AM et al (1992) High-dose methotrexate in the treatment of malignant mesothelioma of the pleura: A phase II study. Br J Cancer 65:956-960
52. Vogelzang NJ, Weissman LB, Herndon JE 2nd et al (1994) Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B Phase II study. J Clin Oncol 12:1436-1442 (Pubitemid 24206243)
53. van Meerbeeck J, Debruyne C, van Zandwijk N et al (1996) Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group. Br J Cancer 74:961-963 (Pubitemid 26319333)
54. Steele JP, O'Doherty CA, Shamash J et al (2001) Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma. Ann Oncol 12:497-499 (Pubitemid 32472104)
55. van Meerbeeck JP, Baas P, Debruyne C et al (1999) A phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Cancer 85:2577-2582
56. Byrne MJ, Davidson JA, Musk AWet al (1999) Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 17:25-30 (Pubitemid 29022374)
57. van Haarst JM, Baas P, Manegold CH et al (2002) Multicenter phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer 86:342-345 (Pubitemid 34187648)
58. Schutte W, Blakenburg T, Lauerwald K et al (2003) A multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma. Clin Lung Cancer 4:294-297 (Pubitemid 36546414)
59. Talbot D, Margery J, Dabuis G et al (2005) Interim results of the phase II study of vinflunine (VFL) in malignant pleural mesothelioma (MPM). Proceedings of the ASCO 41st Annual Meeting, June 1-5, 2005 Orlando, FL, USA, J Clin Oncol 23[Suppl 16]: [Abstract #7171]
60. Berghmans T, Paesmans M, Lalami Y et al (2002) Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 38:111-121 (Pubitemid 35157753)
61. Goldman ID, Zhao R (2002) Molecular, biochemical, and cellular pharmacology of pemetrexed. Semin Oncol 29[Suppl 18]: 3-17 (Pubitemid 36176669)
62. Scagliotti GV, Shin DM, Kindler HL et al (2003) Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 21:1556-1561 (Pubitemid 46594110)
63. Vogelzang MJ, Rusthoven JJ, Symanowski J et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 1:2636-2644. (Pubitemid 46606305)
64. Jackman AL, Taylor GA, Gibson W et al (1991) ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumour cell growth in vitro and in vivo: A new agent for clinical study. Cancer Res 51:5579-5586
65. Baas P, Ardizzoni A, Grossi F et al (2003) EORTC Lung Cancer Group: The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: An EORTC phase II study (08992). Eur J Cancer 39:353-357 (Pubitemid 36140053)
66. Fizazi K, Doubre H, Le Chevalier T et al (2003) Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: Results of a phase II study. J Clin Oncol 21:349-354 (Pubitemid 46606165)
67. Van Meerbeeck P, Gaafar R, Manegold C et al (2005) Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organization for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23:6881-6889
68. Teicher BA, Chen V, Shih C et al (2000) Treatment regimens including the multitargeted antifolate LY231514 in human tumour xenografts. Clin Cancer Res 6:1016-1023 (Pubitemid 30159362)
69. Hughes A, Calvert P, Azzabi A et al (2002) Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol 20:3533-3544
70. Ceresoli GL, Zucali PA, Favaretto AG et al (2006) Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 24:1443-1448 (Pubitemid 46622011)
71. Muers M, Fisher P, Snee M et al on behalf of the MS01 Trial Management Group. A randomized phase III trial of active symptom control (ASC) with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma: First results of the Medical Research Council (MRC)/British Thoracic Society (BTS) MS01 trial. Proceedings of the ASCO 43rd Annual Meeting June 1-5, 2007 Chicago, IL, USA, J Clin Oncol 2007;25 [Suppl 18S]:[Abstract #7525]
72. O'Brien MER, Watkins D, Ryan C et al (2006) A randomized trial in malignant mesothelioma of early versus delayed chemotherapy in symptomatically stable patients: the MED trial. Ann Oncol 17:270-275 (Pubitemid 43160117)
73. Destro A, Ceresoli GL, Falleni M et al (2006) EGFR overexpression in malignant pleural mesothelioma: An immunohistochemical and molecular study with clinico-pathological correlations. Lung Cancer 51:207-215 (Pubitemid 43144364)
74. Edwards JG, Swinson DE, Jones JL et al (2006) EGFR expression: Associations with outcome and clinicopathological variables in malignant pleural mesothelioma. Lung Cancer 54:399-407 (Pubitemid 44634142)
75. Govindan R, Kratzke RA, Herndon JE et al (2005) On behalf of the Cancer and Leukemia Group B. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 11:2300-2304 (Pubitemid 40490190)
76. Garland LL, Rankin C, Gandara DR et al (2007) Phase II Study of Erlotinib in Patients With Malignant Pleural Mesothelioma: A Southwest Oncology Group Study. J Clin Oncol 25:2406-2413 (Pubitemid 46999211)
77. Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139 (Pubitemid 38637993)
78. Cortese JF, Gowda AL, Wali A et al (2006) Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma. Int J Cancer 118:521-522 (Pubitemid 41779097)
79. Ohta Y, Shridhar V, Bright RK et al (1999) VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 81:54-61 (Pubitemid 29415491)
80. Aoe K, Hiraki A, Tanaka T et al (2006) Expression of vascular endothelial growth factor in malignant mesothelioma. Anticancer Res 26:4833-4836 (Pubitemid 46032120)
81. Masood R, Kundra A, Zhu S et al (2003) Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops. Int J Cancer 104:603-610 (Pubitemid 36337260)
82. Karrison T, Kindler HL, Gandara DR et al. Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM). Proceedings of the ASCO 43rd Annual Meeting June 1-5, Chicago, IL, USA. J Clin Oncol 2007;25[Suppl 18]:752
83. Janne PA, Wang XF, Krug LM et al. Sorafenib in malignant mesothelioma (MM): A phase II trial of the Cancer and Leukemia Group B (CALGB 30307). Proceedings of the ASCO 43rd Annual Meeting June 1-5, 2007 Chicago, IL, USA. J Clin Oncol 25[Suppl 18]:7707
84. Fine HA, Figg WD, Jaeckle K et al (2000) Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 18:708-715 (Pubitemid 30106600)
85. Baas P, Boogerd W, Dalesio O et al (2005) Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer 48:291-296
86. Jahan TM, Gu L, Wang X et al (2006)Vatalanib (V) for patients with previously untreated advanced malignant mesothelioma (MM): A phase II study by the Cancer and Leukemia Group B (CALGB 30107). Proceedings of the ASCO 42nd Annual Meeting June 2-6, 2006 Atlanta, GA, USA. J Clin Oncol 24[Suppl 18]:7081
87. Kelly WK, O'Connor OA, Krug L et al (2005) Phase I study of the oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23:3923-3931 (Pubitemid 46218695)
88. O'Connor OA, Heaney ML, Schwartz L et al (2006) Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 24:166-173 (Pubitemid 46630509)
89. Krug LM, Curley T, Schwartz L et al (2006) Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer 7:257-261 (Pubitemid 43280028)
90. Larsson O, Girnita A, Girnita L (2005) Role of insulin-like growth factor 1 receptor signalling in cancer. Br J Cancer 92:2097-2101 (Pubitemid 40966242)
91. Hoang CD, D'Cunha J, Kratzke MG, et al (2004) Gene expression profiling identifies matriptase overexpression in malignant mesothelioma. Chest 125:1843-1852 (Pubitemid 38648420)
92. Scotlandi K, Manara MC, Nicoletti G et al (2005) Antitumour activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumours. Cancer Res 65:3868-3876. (Pubitemid 40616368)
93. Whitson BA, Jacobson BA, Frizelle S et al (2006) Effects of insulin-like growth factor-1 receptor inhibition in mesothelioma. Thoracic Surgery Directors Association Resident Research Award. Ann Thorac Surg 82:996-1001
94. Bepler G, Kusmartseva I, Sharma S et al (2006) RRM1-modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 24:4731-4737 (Pubitemid 46646245)
95. Zheng Z, Chen T, Li X et al (2007) DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 356:800-808 (Pubitemid 46294612)
96. Ceppi P, Volante M, Saviozzi S et al (2006) Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 107:1589-1596 (Pubitemid 44546920)
97. Nakano J, Huang C, Liu D et al (2006) Evaluations of biomarkers associated with 5-FU sensitivity for non-small-cell lung cancer patients postoperatively treated with UFT. Br J Cancer 95:607-615 (Pubitemid 44325901)
98. Flynn J, Berg RW, Wong T et al (2006) Therapeutic potential of antisense oligodeoxynucleotides to down-regulate thymidylate synthase in mesothelioma. Mol Cancer Ther 5:1423-1433 (Pubitemid 44070478)
99. Kosuri KV and Otterson G. The role of methylation leading to capecitabine resistant malignant mesothelioma. Proceedings of the ASCO 42nd Annual Meeting June 2-6, 2006 Atlanta, GA, USA. J Clin Oncol 24[Suppl 18S]: [Abstract #17105]
100. Gordon GJ, Rockwell GN, Godfrey PA et al (2005) Validation of genomicsbased prognostic tests in malignant pleural mesothelioma. Clin Cancer Res 11:4406-4414 (Pubitemid 40825631)
101. Gordon GJ, Mani M, Mukhopadhyay L et al (2007) Inhibitor of apoptosis proteins are regulated by tumour necrosis factor-alpha in malignant pleural mesothelioma. J Pathol 211:439-446 (Pubitemid 46332555)
102. Gordon GJ, Mani M, Mukhopadhyay L et al (2007) Expression patterns of inhibitor of apoptosis proteins in malignant pleural mesothelioma. J Pathol 211:447-454 (Pubitemid 46332556)
103. Fennell D, Steele J, Sheaff M et al. Response of malignant pleural mesothelioma to chemotherapy does not confer a survival advantage. Proceedings of the 11th World Conference on Lung Cancer, 3-6 July 2005, Barcelona, Spain. Lung Cancer 49[Suppl 2]:[Abstract #P-397]
104. Gordon GJ, Rockwell GN, Godfrey PA et al (2005) Validation of genomicsbased prognostic tests in malignant pleural mesothelioma. Clin Cancer Res 11:4406-4414 (Pubitemid 40825631)
105. Pass HI, Liu Z, Wali A et al (2004) Gene expression profiles predict survival and progression of pleural mesothelioma. Clin Cancer Res 10:849-859 (Pubitemid 38198883)
106. Singhal S, Wiewrodt R, Malden LD et al (2003) Gene expression profiling of malignant mesothelioma. Clin Cancer Res 9:3080-3097 (Pubitemid 36993271)
107. López-Ríos F, Chuai S, Flores R et al (2006) Global Gene Expression Profiling of Pleural Mesotheliomas: Overexpression of Aurora Kinases and P16/CDKN2A Deletion as Prognostic Factors and Critical Evaluation of Microarray-Based Prognostic Prediction. Cancer Research 66: 2970-2979